Advancements in the design and scalable production of viral gene transfer vectors
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The last 10 years have seen a rapid expansion in the use of viral gene transfer vectors, with approved therapies and late stage clinical trials underway for the treatment of genetic disorders, and multiple forms of cancer, as well as prevention of infectious diseases through vaccination. With this increased interest and widespread adoption of viral vectors by clinicians and biopharmaceutical industries, there is an imperative to engineer safer and more efficacious vectors, and develop robust, scalable and cost‐effective production platforms for industrialization. This review will focus on major innovations in viral vector design and production systems for three of the most widely used viral vectors: Adenovirus, Adeno‐Associated Virus, and Lentivirus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341 · cited 1×
“Second, the packaging plasmid is split into two separate plasmids, with rev expressed on one and GAG and POL expressed the other, increasing the number of recombination events required to form a replication competent virus (Dull et al., 1998).”
BackgroundAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 1×
“Trials for adenovirus-vectored Ebola vaccines utilize doses in the range of 1010–1011 viral particles per patient, while AAV-vectored therapies for Hemophilia B use doses as high as 2 × 1012 viruses per kilogram of patient bodyweight (Ledgerwood et al., 2017; Nathwani et al., 2011).”
BackgroundDevelopment of a self-inactivating lentivirus vector
Miyoshi, H., Blömer, U., Takahashi, M., Gage, F. H., & Verma, I. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.10.8150-8157.1998 · Cited by 1,196 · cited 1×
“Risk of transactivation of proto-oncogenes can be further reduced with the use of third generation SIN lentiviral vectors where promotor elements in the 3′ LTR of the virus are deleted, preventing transactivation of nearby genes (Knight, Bokhoven, Collins, & Takeuchi, 2010; Miyoshi et al., 1998).”
BackgroundLentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome
Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M. P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M. C., et al. (2013) · Science · doi:10.1126/science.1233151 · Cited by 1,025
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926 · cited 4×
“AAV serotypes 1–9 are the best characterized, capable of transducing a range of tissues, with most vector systems utilizing AAV2 as the vector backbone (Daya & Berns, 2008).”
BackgroundInfluentialLong-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743 · cited 1×
“…use of viral vectors in the coming years; viral vectored vaccines, chimeric antigen receptor (CAR) T-cell therapies for cancers, and treatments for a myriad of genetic disorders are entering phase II and III clinical trials (Bainbridge et al., 2015; Ewer et al., 2016; Wang, Guo, & Han, 2017).”
BackgroundMcCarty, D., Monahan, P., & Samulski, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301514 · Cited by 735 · cited 1×
“These vectors show stronger transcription and higher transduction efficiency compared to ssAAVvectors (Gruenert et al., 2016;McCarty, 2008;McCarty et al., 2001).”
BackgroundParks, R. J., Chen, L., Anton, M., Sankar, U., Rudnicki, M. A., & Graham, F. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13565 · Cited by 725
LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus
Finkelshtein, D., Werman, A., Novick, D., Barak, S., & Rubinstein, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214441110 · Cited by 656
Directed evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538
Self-complementary AAV vectors; advances and applications
McCarty, D. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.171 · Cited by 515 · cited 1×
“These vectors show stronger transcription and higher transduction efficiency compared to ssAAVvectors (Gruenert et al., 2016;McCarty, 2008;McCarty et al., 2001).”
BackgroundGrimm, D., Kay, M. A., & Kleinschmidt, J. A. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00095-9 · Cited by 344
Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency
Wilson, J. M. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.12.016 · Cited by 299
Production of lentiviral vectors
Merten, O.-W., Hebben, M., & Bovolenta, C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.17 · Cited by 294
Manufacturing of recombinant adeno-associated viral vectors for clinical trials
Clément, N., & Grieger, J. C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.2 · Cited by 286
In vivo model of adeno-associated virus vector persistence and rescue
Afione, S. A., Conrad, C. K., Kearns, W. G., Chunduru, S., Adams, R., Reynolds, T. C., Guggino, W. B., Cutting, G. R., Carter, B. J., & Flotte, T. R. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3235-3241.1996 · Cited by 223 · cited 2×
“thus expression typically declines as a function of cell division rate (Afione et al., 1996).”
BackgroundAdeno-Associated Virus Integration: Virus versus Vector
Smith, R. H. (2008) · Gene Therapy · doi:10.1038/gt.2008.55 · Cited by 178
Wu, Z., Sun, J., Zhang, T., Yin, C., Yin, F., Van Dyke, T., Samulski, R. J., & Monahan, P. E. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300355 · Cited by 153 · cited 1×
“…in a variety of tissues provide strong in vivo evidence that although ssAAV vectors “catch up” to a certain extent, scAAV vectors show consistently higher transgene expression and transduction efficiency months after administration (Bell et al., 2016; Natkunarajah et al., 2008; Wu et al., 2008).”
BackgroundNatkunarajah, M., Trittibach, P., McIntosh, J., Duran, Y., Barker, S. E., Smith, A. J., Nathwani, A. C., & Ali, R. R. (2008) · Gene Therapy · doi:10.1038/sj.gt.3303074 · Cited by 138 · cited 1×
“…in a variety of tissues provide strong in vivo evidence that although ssAAV vectors “catch up” to a certain extent, scAAV vectors show consistently higher transgene expression and transduction efficiency months after administration (Bell et al., 2016; Natkunarajah et al., 2008; Wu et al., 2008).”
BackgroundInsertional Gene Activation by Lentiviral and Gammaretroviral Vectors
Bokhoven, M., Stephen, S. L., Knight, S., Gevers, E. F., Robinson, I. C., Takeuchi, Y., & Collins, M. K. (2009) · Journal of Virology · doi:10.1128/jvi.01865-08 · Cited by 138 · cited 1×
“However, the integrative nature of the vector also introduces the risk of insertional mutagenesis (IM), particularly proto-oncogene activation (Bokhoven et al., 2009).”
BackgroundTransient transfection methods for clinical adeno-associated viral vector production
Wright, J. F. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.064 · Cited by 131 · cited 1×
“Polyethylenimine (PEI) is generally preferred as the transfection reagent, being relatively cost-effective compared to cationic lipids, but less sensitive to fluctuations in pH and dissolved solutes compared to calcium phosphate methods (Wright, 2009).”
BackgroundThe Mre11/Rad50/Nbs1 complex limits adeno-associated virus transduction and replication
Schwartz, R. A., Palacios, J. A., Cassell, G. D., Adam, S., Giacca, M., & Weitzman, M. D. (2007) · Journal of Virology · doi:10.1128/jvi.01523-07 · Cited by 130
Immune responses to AAV-vectors, the Glybera example from bench to bedside
Ferreira, V., Petry, H., & Salmon, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00082 · Cited by 120
Construction of stable packaging cell lines for clinical lentiviral vector production
Sanber, K. S., Knight, S. B., Stephen, S. L., Bailey, R., Escors, D., Minshull, J., Santilli, G., Thrasher, A. J., Collins, M. K., & Takeuchi, Y. (2015) · Scientific Reports · doi:10.1038/srep09021 · Cited by 108
Koo, T., Popplewell, L., Athanasopoulos, T., & Dickson, G. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.164 · Cited by 104
Structural Analysis of Adeno-Associated Virus Transduction Circular Intermediates
Duan, D., Yan, Z., Yue, Y., & Engelhardt, J. F. (1999) · Virology · doi:10.1006/viro.1999.9821 · Cited by 100
Properties of the Adeno-Associated Virus Assembly-Activating Protein
Naumer, M., Sonntag, F., Schmidt, K., Nieto, K., Panke, C., Davey, N. E., Popa-Wagner, R., & Kleinschmidt, J. A. (2012) · Journal of Virology · doi:10.1128/jvi.01675-12 · Cited by 97
Manufacturing of recombinant adeno-associated viruses using mammalian expression platforms
Robert, M., Chahal, P. S., Audy, A., Kamen, A., Gilbert, R., & Gaillet, B. (2017) · Biotechnology Journal · doi:10.1002/biot.201600193 · Cited by 89
Self-citationOptimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes
Maersch, S., Huber, A., Büning, H., Hallek, M., & Perabo, L. (2010) · Virology · doi:10.1016/j.virol.2009.10.021 · Cited by 50
Bell, P., Wang, L., Chen, S.-J., Yu, H., Zhu, Y., Nayal, M., He, Z., White, J., Lebel-Hagan, D., & Wilson, J. M. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.039 · Cited by 26
Cited by
MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer
Zhang, L., Liao, Y., & Tang, L. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1059-5 · Cited by 510
Poly (amidoamine) (PAMAM) dendrimer mediated delivery of drug and pDNA/siRNA for cancer therapy
Li, J., Liang, H., Liu, J., & Wang, Z. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.05.045 · Cited by 281
Casazza, J. P., Cale, E. M., Narpala, S., Yamshchikov, G. V., Coates, E. E., Hendel, C. S., Novik, L., Holman, L. A., Widge, A. T., Apte, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01762-x · Cited by 91
Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies
Rocamora, F., Peralta, A. G., Shin, S., Sorrentino, J., Wu, M. Y. M., Toth, E. A., Fuerst, T. R., & Lewis, N. E. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108206 · Cited by 67
Lucas, C., Blackman, M., Rayat, A., Mainwaring, D., & Micheletti, M. (2024) · Journal of Advanced Manufacturing and Processing · doi:10.1002/amp2.10180 · Cited by 4
Metadata
- Authors
- Sharon, D., & Kamen, A.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2017-10-30
- Volume
- 115
- Issue
- 1
- Pages
- 25-40
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2758103344
- Cited by
- 59
- References
- 31
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.